Mutations in the gap junction protein connexin47 (Cx47) are associated with lymphedema. However, the role of Cx47 in lymphatic pathophysiology is unknown. We demonstrate that Cx47 is expressed in lymphatic endothelial cells by whole-mount immunostaining and qPCR. To determine if Cx47 plays a role in lymphatic vessel function we analysed Cx47-/- mice. Cx47-deficiency did not affect lymphatic contractility (contractile amplitude or frequency) or lymphatic morphology (vessel diameter or number of valves). Interstitial fluid drainage or dendritic cell migration through lymphatic vessels was also not affected by Cx47-deficiency. Cx47 is dispensable for long-chain fatty acid absorption from the gut but rather promotes serum lipid handling as prolonged elevated triglyceride levels were observed in Cx47-deficient mice after oral lipid tolerance tests. When crossed with Apolipoprotein E-deficient (Apoe-/-) mice, LDL-cholesterol was decreased in young Cx47-/-Apoe-/- adults as compared to Apoe-/- mice, which was inverted later in life. Finally, advanced atherosclerotic plaques in thoracic-abdominal aortas of 15 months-old mice tended to be larger in Cx47-/-Apoe-/- mice. These plaques contained fewer macrophages but similar amounts of T lymphocytes, collagen and lipids than plaques of Apoe-/- mice. In conclusion, Cx47 is expressed in lymphatic endothelium and seems modestly implicated in multiple aspects of lymphatic pathophysiology.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521787 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0181476 | PLOS |
Cardiovasc Res
December 2024
Department of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Aim: Microcalcification increases the vulnerability of plaques and has become an important driver of acute cardiovascular events in diabetic patients. However, the regulatory mechanisms remain unclear. DJ-1, a multifunctional protein, may play a potential role in the development of diabetic complications.
View Article and Find Full Text PDFBackground: Apolipoprotein ε4 allele (APOE4) is the strongest genetic risk factor for late-onset Alzheimer's disease (AD) with females having higher risk than males. Compared with non-carriers, cognitively normal, middle-aged APOE4 carriers have lower cerebral blood flow (CBF) decades before clinical symptoms appear. Early intervention to protect CBF would be critical for APOE4 carriers to mitigate AD progression.
View Article and Find Full Text PDFBackground: Frequently utilized Alzheimer's disease (AD) preclinical models rely on risk factors expressed in familial AD, which accounts for <1% of the clinical AD population. Apolipoprotein (APOE) ε4 is the strongest genetic risk factor for the development of the more prevalent late-onset Alzheimer's disease (LOAD). MRI studies demonstrate a link between APOE-ε4 and reduced gray matter volume as well as lower fractional anisotropy (FA) in AD patients.
View Article and Find Full Text PDFBackground: Two main risk factors of Alzheimer's disease (AD) are aging and APOE-ε4. However, some individuals remain cognitively normal despite having these risk factors. They are considered "cognitively resilient".
View Article and Find Full Text PDFBackground: Recent studies show apolipoprotein E4 (APOE4), the strongest known genetic risk factor for late-onset Alzheimer's disease, is associated with vascular dysfunctions such as blood-brain barrier breakdown, in both animal models and humans. However, there is a lack of understanding on how vascular alterations progress with age in APOE4.
Method: Human APOE4 (m/f, n=10 per group) and APOE3 targeted replacement mice (m, n=10) were used to investigate temporal dynamics of long-term, progressive cerebral microvascular alterations in APOE4.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!